Ablynx NV has presented more positive data for caplacizumab - which looks set to become the first drug approved for rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP) - that highlight potential selling points likely to win over payers if the drug is successful with regulators.
Analysts have called caplacizumab a "game changer" for Ablynx since the company reported the positive data for the drug this week. The additional data from the Phase III HERCULES trial were published on Dec